TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03602313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Weight Support Gait Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Gait Training
Study: NCT01767493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Florbetapir PET imaging
Description: \[18F\]Florbetapir and PET imaging
Study: NCT04768959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FelizMente
Description: The intervention aims to improve well-being, without denying the existence of symptoms or problems, focusing on generating positive emotions and actions congruent with the person's values through 11 weekly 90-minute group sessions. The multi-component intervention manual was composed of evidence-based exercises of Positive Psychoterapy Interventions, Acceptance and Commitment Therapy and Mindfulness and was theory driven according the broaden-and-build-theory (Fredrickson, 2001) and the self-serving model of paranoia (Murphy et al., 2018). It was also informed by previous pilot studies carried out on people with paranoid tendencies (see Valiente et al., 2020) and with Severe Psyquiatric Condition samples.
Study: NCT02764723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: 12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isobaric ropivacaine
Description: 15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
Study: NCT01056003

Intervention type: OTHER
Intervention: Endoscopy
Description: observational endoscopy in all patients an EGD is planned anyway
Study: NCT04463628

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: The study questionnaire was constructed as follows:~* One part is composed of validated questionnaires: Cystic fibrosis specific self-questionnaire for quality of life, questionnaire for screening for anxiety disorder.~* The other part, which was not validated, was constructed as follows: questionnaire on knowledge of Covid-19 adapted to the new exceptional situation (Covid-19 pandemic) and specific questions adapted to the research objective on Covid-19 from the questionnaire of the French Public Health survey, to monitor changes in behaviour and mental health during lockdown

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Two interviews in the human and social sciences, conducted by recorded video-conference, will be proposed to 15 patients during and after the lockdown.Two interviews will take place: one during the lockdown and one at 6 months from the first interview (or at the end of the confinement if it lasts more than 6 months). The interviews will be conducted independently of the results of the questionnaire.
Study: NCT03789032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Vadadustat 300 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Oral Rabeprazole
Study: NCT03442257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: The experimental treatment will consist of health promoting text messages addressing metabolic risk factors associated with cardiovascular disorders in patients with hypertension. Participants will receive four semi-personalized messages per week in addition to their usual care. The text messages will be developed to support healthy life style changes i.e. regarding general cardiovascular health, tobacco use, physical activity and diet.
Study: NCT00387374

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study: NCT02046226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygenesys(TM) Dissolved Oxygen Dressing
Description: OxyGenesys(TM) Dissolved Oxygen Dressing
Study: NCT00974688

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Intervention
Description: The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Intervention
Description: The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration Intervention
Description: The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Demonstration Intervention
Description: The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
Study: NCT03668054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Lumiere®)
Description: The first three doses of bevacizumab (Lumiere®) were administered via intravitreal injection on a monthly basis. A safety evaluation was conducted in the first month. Following the first three doses, continuation of the treatment (up to 6 doses) was decided according to response.
Study: NCT01457950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: double-blind phase: 60mg subcutaneous injection, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: double-blind phase: placebo subcutaneous injection, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: open-label denosumab
Description: open-label phase: 60mg subcutaneous injection, single dose
Study: NCT03481920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Human Hyaluronidase (PEGPH20)
Description: PEGPH20 will be administered at a dose of 3.0 micrograms per kilogram (μg/kg) as an intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be administered as at a dose of 10 milligrams per kilogram (mg/kg) as an intravenous (IV) infusion once every 2 weeks.
Study: NCT03027726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle and psycho-educational program
Description: The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise plus lifestyle and psycho-educational program
Description: The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
Study: NCT04859881

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04082325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF88434
Description: Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF88434
Description: Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF88434
Description: Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF88434
Description: Lu AF88434, single oral solution Starting dose will be 0.2 mg, actual doses for following cohorts will be defined based on results from preceding dosing group(s).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF99722 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF99723 14C spiked dosage ([14C]-radiolabelled Lu AF88434)
Description: Oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to Lu AF88434 oral solution, single dose
Study: NCT00805311

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy
Description: CEA involves a neck incision and physical removal of the plaque from the inside of the artery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin, aspirin, losartan, amlodipine
Description: aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin, aspirin, losartan, amlodipine
Description: aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
Study: NCT04389424

Intervention type: DRUG
Intervention: Tamoxifen
Description: Use of tamoxifen for breast cancer recurrence prevention

Intervention type: DRUG
Intervention: Tamoxifen
Description: Use of tamoxifen for breast cancer recurrence prevention

Intervention type: DRUG
Intervention: Exemestane
Description: Use of exemestane for breast cancer recurrence prevention

Intervention type: DRUG
Intervention: Anastrozole
Description: Use of anastrozole for breast cancer recurrence prevention

Intervention type: DRUG
Intervention: Anastrozole
Description: Use of anastrozole for breast cancer recurrence prevention

Intervention type: DIAGNOSTIC_TEST
Intervention: Basal
Description: Initial diagnosis of breast cacner by biopsy or mastectomy

Intervention type: DIAGNOSTIC_TEST
Intervention: Recurrence
Description: Breast cancer recurrence under endocrine therapy
Study: NCT02316041

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction
Description: The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReLEx® (SMILE)
Study: NCT05266742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web based education
Description: An educative website was created for our study. The content of the website was accessible from www.diyabet.mumcu.net and the content of the website was brought together by scanning the literature. The content text was quoted from publicly available information and guides as ADA and IDF.
Study: NCT00298545

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo and Calcitriol
Description: Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Calcitriol
Description: Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
Study: NCT00815009

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Mod Fat/Low Processed Carb Diet and Moderate Exercise
Description: Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
Study: NCT04774744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Receive standard of care support services
Study: NCT02934867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol phone advice
Description: Protocol phone advice

Intervention type: OTHER
Group type: OTHER
Intervention: Usual phone advice
Description: Usual phone advice
Study: NCT04017650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study: NCT00815009

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mod Fat/Low Processed Carb Diet and Moderate Exercise
Description: Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mod Fat/Low Processed Carb Diet and Moderate Exercise
Description: Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mod Fat/Low Processed Carb Diet and Moderate Exercise
Description: Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Fat Diet and Moderate Exercise
Description: Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise Only
Description: No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
Study: NCT04277156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus ATCC 53103 & Lactobacillus reuteri DSM 29063
Description: 7 drops contain Lactobacillus rhamnosus GG 5x10\^9 CFU; and Lactobacillus reuteri 1x10\^8 CFU.
Study: NCT02025244

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Key Hole Biopsy ( KHB)
Description: Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Key Hole Biopsy ( KHB)
Description: Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-FNA
Description: Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
Study: NCT03258190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lime Powder Regimen
Description: LPR and placebo were randomly given to subjects for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lime Powder Regimen
Description: LPR and placebo were randomly given to subjects for 6 months
Study: NCT01979809

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MENU GenY
Description: Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MENU GenY
Description: Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MENU GenY
Description: Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
Study: NCT04178499

Intervention type: DIAGNOSTIC_TEST
Intervention: cytokine analysis
Description: analysis of intraocular cytokines

Intervention type: DIAGNOSTIC_TEST
Intervention: cytokine analysis
Description: analysis of intraocular cytokines
Study: NCT03164200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat breakfast
Description: High fat breakfast

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher carbohydrate breakfast
Description: Higher carbohydrate breakfast
Study: NCT00399360

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 mg twice daily increasing to 850 mg twice daily after 3 Months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 500 mg twice daily increasing to 850 mg twice daily after 3 Months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Lifestyle Modification

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle Modification
Description: Lifestyle Modification
Study: NCT03564145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S5G4T-1
Description: Once a day topical cream
Study: NCT03021239

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echo Guided Testing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic-Echo Ramp Testing -
Study: NCT04017650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04107792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parental sense of competence workshop
Description: The intervention will be a two-hour parent education workshop that provides education and teaches parent-mediated strategies for managing children's behaviours associated with SPIs.